Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 55

1.

Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.

Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, Messner EJ, White JA, Melnick JZ, Bishop CW.

Am J Nephrol. 2014;40(6):535-45. doi: 10.1159/000369939. Epub 2015 Jan 7.

2.

Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation.

Petkovich M, Melnick J, White J, Tabash S, Strugnell S, Bishop CW.

J Steroid Biochem Mol Biol. 2015 Apr;148:283-9. doi: 10.1016/j.jsbmb.2014.11.022. Epub 2014 Nov 22.

3.

The effects of preceding lead-alone and lag-alone click trains on the buildup of echo suppression.

Bishop CW, Yadav D, London S, Miller LM.

J Acoust Soc Am. 2014 Aug;136(2):803-17. doi: 10.1121/1.4874622.

4.

Neural time course of visually enhanced echo suppression.

Bishop CW, London S, Miller LM.

J Neurophysiol. 2012 Oct;108(7):1869-83. doi: 10.1152/jn.00175.2012. Epub 2012 Jul 11.

5.

Auditory grouping mechanisms reflect a sound's relative position in a sequence.

Hill KT, Bishop CW, Miller LM.

Front Hum Neurosci. 2012 Jun 8;6:158. doi: 10.3389/fnhum.2012.00158. eCollection 2012.

6.

Spatial attention modulates the precedence effect.

London S, Bishop CW, Miller LM.

J Exp Psychol Hum Percept Perform. 2012 Dec;38(6):1371-9. doi: 10.1037/a0028348. Epub 2012 Apr 30.

7.

Speech cues contribute to audiovisual spatial integration.

Bishop CW, Miller LM.

PLoS One. 2011;6(8):e24016. doi: 10.1371/journal.pone.0024016. Epub 2011 Aug 31.

8.

Pattern of BOLD signal in auditory cortex relates acoustic response to perceptual streaming.

Hill KT, Bishop CW, Yadav D, Miller LM.

BMC Neurosci. 2011 Aug 17;12:85. doi: 10.1186/1471-2202-12-85.

9.

Methods to eliminate stimulus transduction artifact from insert earphones during electroencephalography.

Campbell T, Kerlin JR, Bishop CW, Miller LM.

Ear Hear. 2012 Jan-Feb;33(1):144-50. doi: 10.1097/AUD.0b013e3182280353.

10.

Visual influences on echo suppression.

Bishop CW, London S, Miller LM.

Curr Biol. 2011 Feb 8;21(3):221-5. doi: 10.1016/j.cub.2010.12.051. Epub 2011 Jan 27.

11.

Neural mechanisms for illusory filling-in of degraded speech.

Shahin AJ, Bishop CW, Miller LM.

Neuroimage. 2009 Feb 1;44(3):1133-43. doi: 10.1016/j.neuroimage.2008.09.045. Epub 2008 Oct 15.

12.

A multisensory cortical network for understanding speech in noise.

Bishop CW, Miller LM.

J Cogn Neurosci. 2009 Sep;21(9):1790-805. doi: 10.1162/jocn.2009.21118.

13.

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.

Am J Kidney Dis. 2004 May;43(5):877-90.

PMID:
15112179
14.

Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone.

Upton RA, Knutson JC, Bishop CW, LeVan LW.

Nephrol Dial Transplant. 2003 Apr;18(4):750-8.

15.

Use of vitamin D(4) analogs to investigate differences in hepatic and target cell metabolism of vitamins D(2) and D(3).

Byford V, Strugnell S, Coldwell R, Schroeder N, Makin HL, Knutson JC, Bishop CW, Jones G.

Biochim Biophys Acta. 2002 Jul 11;1583(2):151-66.

PMID:
12117559
16.

Prostate cancer prevention strategies using antiproliferative or differentiating agents.

Walczak J, Wood H, Wilding G, Williams T Jr, Bishop CW, Carducci M.

Urology. 2001 Apr;57(4 Suppl 1):81-5.

PMID:
11295601
17.

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Maung HM, Elangovan L, Frazão JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.

Am J Kidney Dis. 2001 Mar;37(3):532-43.

PMID:
11228177
18.

Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.

Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW.

Am J Kidney Dis. 2000 Sep;36(3):550-61.

PMID:
10977787
19.

Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum.

Mawer EB, Jones G, Davies M, Still PE, Byford V, Schroeder NJ, Makin HL, Bishop CW, Knutson JC.

J Clin Endocrinol Metab. 1998 Jun;83(6):2156-66.

PMID:
9626155
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk